Empasiprubart for Myasthenia Gravis

(ADAPT Forward2 Trial)

This trial tests a new intravenous treatment called empasiprubart for individuals with generalized myasthenia gravis, a condition that causes muscle weakness. The study aims to determine if this treatment is safe and effective compared to a placebo, which contains no active medicine. Participants will also undergo a follow-up period with another treatment, efgartigimod. Individuals with myasthenia gravis who have certain antibodies and experience muscle weakness might be suitable candidates for this trial. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial requires that you stop taking certain medications, like complement inhibitors, before joining. If you've been on zilucoplan or eculizumab, you need to have stopped them more than 2 months ago, and ravulizumab more than 6 months ago. Other medications are not specifically mentioned, so it's best to discuss with the trial team.

In a previous study, researchers found that empasiprubart was generally well-tolerated. About 21.45% of patients experienced side effects, most of which were mild to moderate. Only 4.29% of patients had serious side effects. This indicates that while side effects can occur, they are not very common. Patients should always consult their doctor about any concerns and to determine if joining a trial is appropriate.¹²³⁴⁵

Empasiprubart IV is unique because it introduces a new approach to treating myasthenia gravis by targeting specific immune pathways. Unlike the standard treatments, such as acetylcholinesterase inhibitors and immunosuppressants, Empasiprubart IV works by modulating the immune system in a novel way, potentially offering better control of symptoms. Researchers are excited about its potential for more effective and faster symptom relief, which could significantly improve the quality of life for patients with this condition.

In this trial, participants will receive either Empasiprubart IV or a placebo. Previous studies have shown that empasiprubart holds promise for treating conditions similar to myasthenia gravis. In another condition, it significantly reduced the need for IVIg, a common treatment for immune disorders, by 91% compared to a placebo. This suggests it might help manage symptoms by reducing the immune system's attacks on muscles. Other research demonstrated improvements in grip strength and patient-reported outcomes in those with muscle-related issues. This evidence offers hope that empasiprubart could effectively enhance muscle strength and daily function for people with myasthenia gravis.¹²⁴⁵⁶